• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Medicare for All: Four Things Health Executives Should Know


No longer a pipe-dream of fringe policy makers, Medicare for All is gaining serious support-and criticism. Here’s what you need to know about the current conversation.

Medicare form

Medicare for All is a proposal that would give all Americans access to healthcare coverage. “The federal government would dictate the terms of the coverage (i.e., the amount of reimbursement for a service or the number of days of coverage for a specific service) and regulate it,” says Christopher J. Kutner, JD, a partner in the law firm Rivkin Radler LLP.

On February 26, more than 100 Democrats in the U.S. House of Representatives announced support for a “Medicare for All” bill, whose chief sponsor is Pramila Jayapal, a Democrat from Washington state. Under the bill, healthcare would be provided to all Americans without premiums, copays, or deductibles. In two years, it would transition the U.S. healthcare system to a single-payer government-funded program. Most likely, no House or Senate Republicans will support it.

Several U.S. Democratic lawmakers have introduced different versions of expanded Medicare or will likely do so. It is expected that Senator Bernie Sanders (I-VT) will reintroduce his bill, which had 16 co-sponsors in the previous session, says Hector De La Torre, executive director of the nonprofit Transamerica Center for Health Studies. There might also be several versions introduced in the House updating retired Congressman John Conyers’ (D-MI) bill, which had 124 co-sponsors in the previous session.

Some of the versions may be a “clean” Medicare for All bill that expands Medicare nationwide into a single payer system; a Medicare buy-in bill that would allow anyone to purchase Medicare while retaining employer-based coverage for others; and a Medicare over 50 bill that would allow individuals between ages 50 and 65 to buy into a Medicare plan while retaining employer-based coverage for others, De La Torre says.

Here are four other things that health executives should know about Medicare for All.

1. House support is growing

A new Medicare for All caucus in the House already has 77 members. In the midterm elections, many Democratic candidates ran and won on a promise to fight to provide all Americans with access to government-run healthcare, Kutner says. All of the likely 2020 Democratic nominees support the idea, too.

2. Private insurance isn't going anywhere

If a Medicare for All healthcare system was employed, some private health insurers would most likely still exist. Despite predictions that private health insurers would cease to exist after the enactment of the ACA in 2010, for-profit health insurers such as United Healthcare and Anthem have continued to prosper-with their stocks rising every year. “I expect those companies to continue to diversify their offerings, moving away from at-risk fully insured products into MedAdvantage plans, Managed Medicaid, and other government-funded plans,” says C. Timothy Gary, JD, MBA, chief executive officer, Crux Strategies, which provides healthcare strategy and legal services.

Related: Opinion: The Need for Value-Based PBMs

Kutner believes some consumers will be willing to pay for additional healthcare coverage and access. In New Zealand, for example, citizens can buy private insurance for treatment in private hospitals, which is desired if they wish to get treated faster, or for non-covered treatments.

Canada doesn’t have private care available, but citizens still have insurance for amenities such as private rooms or services the government doesn’t cover. “This would likely also occur in the United States, where private insurance would most likely be available for individuals who want the best physicians, hospitals, and specialty facilities,” Kutner says.

3. Cost estimates are far reaching

The Mercatus Center at George Mason University issued a study in July 2018 which calculated that the Medicare for All plan proposed by Senator Bernie Sanders would add $32.6 trillion to the federal budget over a 10-year period. The study further indicated that doubling all federal income taxes in place at that time would be insufficient to cover the added costs. To put these numbers into perspective, the U.S. government budget deficit was reported as $665 billion in 2017. “That is an exponential growth in the deficit,” Gary says.

4. Most Americans support it

The vast majority of Americans, roughly 70%, support Medicare for All, according to a new Reuters survey.That includes 85% of Democrats and 52% of Republicans. Only 20% of Americans outright oppose the idea. “Medicare is a very popular program, so the idea of expanding it to everyone is also, not surprisingly, popular,” Kutner says. “The argument in favor of Medicare for All, which is much closer to how the rest of the world provides healthcare to its citizens, is that you can achieve universal coverage at a lower cost.”

Karen Appold is a medical writer in Lehigh Valley, Pennsylvania. 

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.